Cargando…

Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin

Low-dose aspirin is widely used in the primary and secondary prevention of cardiovascular events, but is associated with a range of upper gastrointestinal side effects. In this review, we summarize the rationale for low-dose aspirin therapy, quantify the risk for upper gastrointestinal side effects,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vonkeman, Harald, Meek, Inger, van de Laar, Mart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108704/ https://www.ncbi.nlm.nih.gov/pubmed/21701631 http://dx.doi.org/10.2147/DHPS.S7206

Ejemplares similares

Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort
por: Meek, Inger L, et al.
Publicado: (2014)

Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks
por: Meek, Inger L., et al.
Publicado: (2010)

Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature
por: Meek, Inger L, et al.
Publicado: (2014)

Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study
por: Vonkeman, Harald E, et al.
Publicado: (2007)

Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study
por: Vonkeman, Harald E, et al.
Publicado: (2008)

Low adherence to national guidelines for proton-pump inhibitor prescription in patients receiving combination aspirin and anticoagulation
por: Sharma, Rajani, et al.
Publicado: (2017)

Suboptimal prescribing of proton-pump inhibitors in low-dose aspirin users: a cohort study in primary care
por: de Jong, Hilda J I, et al.
Publicado: (2013)

Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study
por: García Rodríguez, Luis A., et al.
Publicado: (2020)

Modification of gastric cancer risk associated with proton pump inhibitors by aspirin after Helicobacter pylori eradication
por: Cheung, Ka Shing, et al.
Publicado: (2018)

Fr581 EVALUATION OF SEQUENTIAL CHANGES IN THE INTESTINAL FLORA OF PATIENTS TAKING LOW-DOSE ASPIRIN AND A PROTON-PUMP INHIBITOR
por: Hirata, Yuki, et al.
Publicado: (2021)

PB2188: PROTON PUMP INHIBITORS ARE SAFE AND EFFECTIVE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA TREATED WITH LOW-DOSE ASPIRIN
por: Krecak, Ivan, et al.
Publicado: (2023)

High-Dose Proton Pump Inhibitors Are Superior to Standard-Dose Proton Pump Inhibitors in High-Risk Patients With Bleeding Ulcers and High-Risk Stigmata After Endoscopic Hemostasis
por: Zhu, Zhenhua, et al.
Publicado: (2021)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
por: Deolekar, Pradnya, et al.
Publicado: (2023)

The Role of Proton Pump Inhibitors in the Management of Pediatric Eosinophilic Esophagitis
por: Gutiérrez-Junquera, Carolina, et al.
Publicado: (2018)

Proton Pump Inhibitors and the Risk of Adverse Cardiac Events
por: Juurlink, David N., et al.
Publicado: (2013)

Proton pump inhibitors: Review of reported risks and controversies
por: Brisebois, Simon, et al.
Publicado: (2018)

Proton pump inhibitors increase risk of COVID-19
Publicado: (2020)

Use of proton pump inhibitors for the risk of gastric cancer
por: Gao, Huiqin, et al.
Publicado: (2022)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
por: Payrastre, Bernard, et al.
Publicado: (2021)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Critical appraisal of a fixed combination of esomeprazole and low dose aspirin in risk reduction
por: Vachhani, Ravi, et al.
Publicado: (2010)

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics
por: Revaiah, Pruthvi C, et al.
Publicado: (2018)

Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis
por: Chen, Yingxi, et al.
Publicado: (2016)

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients
por: de Francisco, Angel L.M., et al.
Publicado: (2017)

Proton pump inhibitors as a risk factor for norovirus infection
por: PRAG, C., et al.
Publicado: (2017)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Inflammatory microRNAs in gastric mucosa are modulated by Helicobacter pylori infection and proton-pump inhibitors but not by aspirin or NSAIDs
por: Vasapolli, Riccardo, et al.
Publicado: (2021)

Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overuse
por: Savarino, Edoardo, et al.
Publicado: (2022)

Comparison of Proton Pump Inhibitor and Histamine-2 Receptor Antagonist in the Prevention of Recurrent Peptic Ulcers/Erosions in Long-Term Low-Dose Aspirin Users: A Retrospective Cohort Study
por: Chen, Wen-Chi, et al.
Publicado: (2014)

Delirium in the geriatric unit: proton-pump inhibitors and other risk factors
por: Otremba, Iwona, et al.
Publicado: (2016)

Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
por: Shah, Nigam H., et al.
Publicado: (2015)

Increased Proton Pump Inhibitors−Induced Mortality Risk in Hemodialysis Patients
por: Sertorio, Jonas T., et al.
Publicado: (2018)

An Additional Perspective on Proton Pump Inhibitors as Risk Factors for COVID-19
por: Homolak, Jan, et al.
Publicado: (2021)

Proton pump inhibitors and the risk of Alzheimer’s disease and non-Alzheimer’s dementias
por: Torres-Bondia, Francisco, et al.
Publicado: (2020)

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis
por: Hussain, Salman, et al.
Publicado: (2022)

Proton Pump Inhibitor Use and Risk of Serious Infections in Young Children
por: Lassalle, Marion, et al.
Publicado: (2023)

Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study
por: Charlot, Mette, et al.
Publicado: (2011)

Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands
por: Chau, Sek Hung, et al.
Publicado: (2017)

Pancytopenia Due to Possible Drug–Drug Interactions Between Low-Dose Methotrexate and Proton Pump Inhibitors
por: Tao, Dan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tlkj9utarvc2ulg3ill0g90bae